AstraZeneca’s LogicBio Buyout Will Give Other Troubled Gene Therapy Companies Hope
Rock Bottom Prices May Tempt Big Pharma
Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.
You may also be interested in...
Leaders from three companies that have managed to achieve successful turnarounds offered some advice and encouragement to biotechs weathering the current financial downturn at the recent Jefferies Healthcare conference in London.
Big Pharma companies are remaining ‘disciplined’ about their M&A deals, with Merck & Co apparently shying away from a $40bn gamble on Seagen, but the need for replenished pipelines remains.
In this week's podcast edition of Five Must-Know Things: Pfizer takes on AstraZeneca and Merck & Co in prostate cancer; AstraZeneca’s gene therapy acquisition; ex-Sanofi partnering head joins AI start-up; Shionogi and Medicines Patent Pool strike deal for oral COVID antiviral; and Intercept sticks with NASH plans despite missed endpoint.